Yizhou Dong, PhD
img_Yizhou Dong
PROFESSOR | Oncological Sciences

Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device, biotechnology companies, and other outside entities to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their outside financial relationships.

Below are financial relationships with industry reported by Dr. Dong during 2023 and/or 2024. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.

Consulting or Other Professional Services: Examples include, but are not limited to, committee participation, data safety monitoring board (DSMB) membership

  • Arbor Biotechnologies
  • FLAGSHIP LABS 85
  • Merck Sharp & Dohme Corp
  • SIRNAGEN THERAPEUTICS, INC.
  • AgeX Therapeutics, Inc
  • Pfizer Inc., U.S. Pharmaceuticals Group

Equity (Stock or stock options valued at greater than 5% ownership of a publicly traded company or equity of any value in a privately held company)

  • Immunanoengineering Therapeutics, LLC

Founder/Co-Founder/Partner:

  • Immunanoengineering Therapeutics, LLC

Royalty Payments:

  • Massachusetts Institute of Technology
  • Ohio State University

Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.